

PROGRESSIVE'S EVENING STROLL

DATE: 27 March, 2026

Market Snapshot:

After the tepid start, the Index compounded its losses throughout the day and finally settled at 22,819.60 with a loss of 486.85 points. All the sectors ended the day in the red, with PSU Banks and Realty being the major underperformers. From the Broader markets, Midcaps declined by 2.23% and marginally lagged, while Smallcaps ended with a loss of 1.74%.

HOW THE DAY TRENDED



INDICES			
Index	Close	Points	%Chg.
Sensex	73583.22	(1690.23)	(2.25)
Nifty50	22819.60	(486.85)	(2.09)
Nifty Midcap 100	54097.80	(1233.25)	(2.23)
Nifty Small Cap 100	15620.00	(276.55)	(1.74)

SECTORAL GAINERS / LOSERS			
Sectors	Close	Points	%Chg.
NIFTY CAPITAL MKT	4380.40	(126.35)	(2.80)
NIFTY AUTO	24351.95	(706.65)	(2.82)
NIFTY REALTY	670.15	(21.95)	(3.17)
NIFTY PSU BANK	8249.45	(331.60)	(3.86)

NIFTY TOP GAINERS / LOSERS					
Gainers	CMP (Rs)	%Chg.	Losers	CMP (Rs)	%Chg.
ONGC	281.95	4.35	SHRIRAM FINANCE	903.80	(5.45)
WIPRO	191.60	1.35	TMPV	303.20	(4.64)
TCS	2389.80	0.52	RELIANCE	1348.10	(4.60)
BHARTI AIRTEL	1843.90	0.49	INDIGO	4099.50	(4.55)

INDICES LEVELS FOR March 30, 2026

Nifty (future)	
Resistance	23160
Support	22600

Bank Nifty (future)	
Resistance	53370
Support	51750



KEY TAKEAWAYS OF THE DAY

◆ **HFCL board approves Rs580cr preform manufacturing facility through subsidiary:**

The board has approved the setting up of a preform manufacturing facility through its wholly owned subsidiary, HFCL Technologies Private Ltd (HTPL), with an estimated investment of about Rs580cr. The proposed facility will manufacture preform; the basic raw material used for the production of optical fiber. The project will add capacity of about 300–310 metric tonnes per annum.

◆ **Azad Engineering secures 8-year single source supplier partnership with Mitsubishi Heavy Industries Japan:**

The company has secured a prestigious 8-year single source supplier partnership with Mitsubishi Heavy Industries Ltd, Japan for manufacturing hot-section nozzle vanes segments of gas turbine engines. This long-term contract & price agreement represents a significant technological advancement for the Indian precision engineering company, transitioning from cold-section components to critical combustion hot-section turbine components. The partnership will utilize MHI's dedicated lean manufacturing facility to serve global power generation markets, marking a rare achievement for an Indian manufacturing company in this specialized sector.

◆ **Aurobindo Pharma arm ties up with European firm for biosimilars:**

Aurobindo Pharma subsidiary CuraTeQ Biologics has entered into a marketing and distribution agreement with European healthcare and pharmaceuticals company STADA Arzneimittel AG for two biosimilars. Under the agreement, STADA will market and distribute two EMA approved biosimilars developed by CuraTeQ in select European Union territories, including France and Germany. New brand names will be created and registered for each biosimilar.

◆ **Infosys acquires Optimum for USD465mn to deepen healthcare, AI capabilities:**

Indian IT services firm Infosys had entered into separate agreements to acquire US-based technology companies Optimum Healthcare IT and Stratus in all-cash deals. Infosys will buy healthcare consulting firm Optimum Healthcare IT for USD465mn and insurance technology company Stratus for USD95mn.

◆ **Novo Nordisk takes Dr. Reddy's to court over Ozempic-like brand name:**

As Semaglutide, the drug behind weight-loss drug Ozempic, goes off-patent in India and cheaper copies flood the market, Novo Nordisk has moved to defend its flagship brand, kicking off a fresh legal battle with Dr. Reddy's Laboratories over a rival name it says is too close for comfort. The Danish drugmaker has approached the Delhi High Court to block Dr. Reddy's from launching a generic version of Semaglutide under the brand name "Olymviq", arguing that it is phonetically and structurally similar to Ozempic and risks confusing patients and prescribers.

Source: Media Reports



DISCLAIMERS AND DISCLOSURES-

Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India. PSBPL started its operation on the National Stock Exchange (NSE) in 1996. PSBPL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE) for its stock broking services and is Depository Participant with Central Depository Services Limited (CDSL) and is a member of Association of Mutual Funds of India (AMFI) for distribution of financial products.

PSBPL is SEBI registered Research Analyst under SEBI (Research Analysts) Regulations, 2014 with SEBI Registration No. INH000000859/Research Analyst BSE Enlistment No. 5049. PSBPL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years. PSBPL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

PSBPL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Progressive Share Brokers Pvt. Ltd. (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company (s) covered in this report:-

- PSBPL or its associates financial interest in the subject company: NO
- Research Analyst (s) or his/her relative's financial interest in the subject company: NO
- PSBPL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (PSBPL) has not been engaged in market making activity for the subject company.
- PSBPL or its associates actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- PSBPL or its associates may have received any compensation including for brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received compensation for products or services other than brokerage services from the subject company in the past 12 months. PSBPL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of PSBPL or its associates during twelve months preceding the date of distribution of the research report and PSBPL may have co-managed public offering of securities for the subject company in the past twelve months.
- The research analyst has served as officer, director or employee of the subject company: NO
- Registration granted by SEBI and certification from NISM is in no way guarantee performance of the intermediary or provide any assurance of returns to investors

PSBPL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses (if any) may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution publication, availability or use would be contrary to law or regulation or which would subject PSBPL or its group companies to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, the same may be ignored. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of PSBPL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of PSBPL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Terms & Conditions:

This report has been prepared by PSBPL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of PSBPL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and its at discretion of the clients to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. PSBPL will not treat recipients as customers by virtue of their receiving this report.

Registered Office Address:

Progressive Share Brokers Pvt. Ltd,
122-124, Laxmi Plaza, Laxmi Indl Estate,
New Link Rd, Andheri West,
Mumbai—400053, Maharashtra
www.progressiveshares.com | Contact No.:022-40777500.

Compliance Officer:

Ms. Mamatha Poojari,
Email: compliance@progressiveshares.com,
Contact No.:022-40777500.

Grievance Officer:

Email: grievancecell@progressiveshares.com

